相关实验视频

Updated: May 20, 2025

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.1K

膜细胞淋巴瘤:从发病到治疗到2024年及以后的时间

Ashlyn M O'Leary1, Christopher R D'Angelo2

  • 1Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA.

Panminerva medica
|March 27, 2025
PubMed

Insights

薄膜细胞淋巴瘤 (MCL) 是一种罕见的癌症,具有多种亚型和攻击性潜力. 治疗正在发展,如BTK抑制剂和CAR-T细胞等向疗法提供了新的希望.

科学领域:

  • 血液学 血液学 血液学
  • 在瘤学瘤学.
  • 遗传学 遗传学 是一个

背景情况:

  • 薄膜细胞淋巴瘤 (MCL) 是一种罕见的B细胞非霍奇金淋巴瘤,具有多种亚型 (cMCL,LV-MCL,ISMCN).
  • 临床表现范围从惰到侵略,需要量身定制的治疗策略.
  • 标志性的基因变异是t(11;14) 转位,导致CCND1-IGH基因融合.

研究的目的:

  • 审查目前对MCL亚型,其临床变异性和遗传基础的理解.
  • 讨论MCL治疗的不断变化的格局,包括既定和新兴的治疗方式.
  • 突出正在进行的研究前沿和MCL管理的未来方向.

主要方法:

  • 关于MCL分类,病原和治疗策略的文献综述.
  • 分析当前的临床实践和新兴的治疗目标.
  • 对新型药物数据的综合和对具有挑战性的MCL表现的管理.

主要成果:

  • 许多MCL亚型在临床行为和预后方面存在显著差异.
  • 治疗选择已经扩大到传统化疗之外,包括向免疫疗法.
  • 布鲁顿氨酸激酶 (BTK) 抑制剂和CAR-T疗法越来越重要,特别是在复发性/耐药性疾病中.

结论:

  • 最佳的MCL管理需要考虑亚型,遗传特征和疾病阶段.
  • 新兴疗法,如非共价BTK抑制剂和双特异性抗体,有望改善治疗结果.
  • 解决TP53突变MCL和中枢神经系统复发仍然是未来研究的关键领域.
抽象的

No abstract available in PubMed .

更多相关视频

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.3K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

399

相关概念视频

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
450
Cells of the Adaptive Immune Response01:23

Cells of the Adaptive Immune Response

The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
733